Global Market Expansion for SaMD

Start by identifying the target markets and comparing their SaMD classification, regulatory pathways, clinical evidence, cybersecurity, QMS, and documentation requirements. A global strategy can establish a common regulatory foundation while adapting submissions to individual authorities such as FDA, EU regulators, TGA, Health Canada, PMDA, NMPA, ANVISA, and MFDS.

A global SaMD regulatory strategy should map the product’s intended use, risk classification, applicable standards, clinical evidence, technical documentation, cybersecurity requirements, and submission pathways for each target market. Early regulatory gap analysis can identify differences between jurisdictions and help determine which existing documentation can be reused or requires modification.

An existing SaMD approval may provide useful regulatory and technical documentation for expansion, but it does not automatically authorize marketing in another country. The existing classification, clinical evidence, risk documentation, QMS, and technical file should be compared with the new jurisdiction’s requirements to identify additional submissions, evidence, or localization activities.

Multimarket SaMD submissions may require technical documentation, software lifecycle documentation, risk management records, clinical evaluation evidence, QMS documentation, cybersecurity information, and market-specific regulatory forms. The exact requirements depend on the jurisdiction and classification. Existing documentation should be reviewed against each authority’s requirements before preparing country-specific submissions.

FDA, EU MDR, and TGA use different regulatory frameworks and submission processes for SaMD. The manufacturer should first establish the software’s qualification and classification, then determine the applicable pathway, prepare technical and clinical documentation, address risk and cybersecurity requirements, and complete the relevant authority submission for each market.

ISO 13485, IEC 62304, and ISO 14971 are key standards identified for global SaMD development and compliance. ISO 13485 addresses the medical device quality management system, IEC 62304 addresses software lifecycle processes, and ISO 14971 addresses risk management. Additional market-specific standards or regulatory requirements may also apply.

Clinical evidence requirements can differ between regulatory jurisdictions based on the SaMD’s intended purpose, risk classification, and applicable regulatory framework. An existing clinical evidence package may support multiple submissions, but regulators can have different expectations. A market-specific assessment can identify whether existing evidence is sufficient or additional documentation is needed.

Cybersecurity should be considered as part of the SaMD regulatory strategy before entering multiple markets. Requirements can differ by jurisdiction and may involve cybersecurity standards, risk management, testing, documentation, and lifecycle controls. The global regulatory assessment should identify applicable cybersecurity expectations and determine whether the existing software documentation meets them.

Existing approvals and technical documentation can provide a foundation for entering additional regions. The manufacturer should map the approved product against the new market’s classification, regulatory pathway, clinical evidence, QMS, risk management, cybersecurity, and localization requirements. This gap assessment identifies what can be reused and what must be updated or newly submitted.

Changing an in-country representative may require updates to regulatory registrations, authority records, agreements, labeling, or other market-specific documentation. The exact process depends on the jurisdiction. The transition should be planned carefully so that regulatory communications, authorizations, licenses, and ongoing post-market compliance remain continuous during the representative change.